AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Neutral
For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but material correction in several holdings over the potential exposure of quality growth franchises to AI disruption. Lundin Mining Corporation shares rose meaningfully during the fourth quarter after the company raised its 2025 copper production outlook and lowered its cash cost guidance.
Read More
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff
Published: February 26, 2026 by: Proactive Investors
Sentiment: Positive
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS, driving an increase to its price target and reiterated 'buy' rating. Analyst Matthew Weston said the company and the wider sector face a "significant patent cliff" around 2030-and-beyond but argues the FTSE 100 drugmaker is well positioned to manage this with "sector leading replacement power".
Read More
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Read More
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Published: February 13, 2026 by: Proactive Investors
Sentiment: Negative
Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', citing a less favourable earnings trajectory as the drugmaker prioritises revenue growth through escalating research spending. The broker warns the current valuation looks full at 20 times forecast 2026 earnings despite confidence the company can exceed its $80 billion 2030 revenue target.
Read More
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
Published: February 12, 2026 by: MarketBeat
Sentiment: Positive
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.
Read More
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline
Published: February 11, 2026 by: Proactive Investors
Sentiment: Positive
Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at Citi following full-year results and 2026 guidance that the bank described as “reassuring”, with a reiterated target price of £170 and unchanged earnings forecasts. Management confirmed expectations for low double-digit earnings growth in 2026, aligning with consensus, while the medium single- to high single-digit revenue outlook was ahead of market forecasts.
Read More
AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Positive
AstraZeneca PLC delivered robust 2025 results, with 9% product sales growth and a 23.4% operating margin, and raised its dividend. AZN targets $80bn in revenues by 2030, driven by oncology, pipeline launches, and a $50bn US investment; management expresses increasing confidence. Patent expirations loom for key drugs, but pipeline assets and AI-driven innovation are expected to offset risks and sustain growth.
Read More
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Neutral
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
Read More
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Negative
AZN misses Q4 EPS and sales estimates, but rallies after projecting mid-to-high single-digit revenue growth and low double-digit EPS growth for 2026.
Read More
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Read More
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Read More
AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.
Read More
FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete response letter.
Read More
AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA
Published: February 03, 2026 by: WSJ
Sentiment: Negative
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in the first half of 2026.
Read More
AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly injectable weight-management pipeline.
Read More
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Read More
UK drugmakers face tougher test as pharma rally cools
Published: January 16, 2026 by: Proactive Investors
Sentiment: Negative
The next earnings season for European pharmaceuticals is shaping up as a test of discipline rather than momentum, with UK stocks firmly in the spotlight. That is the message from Deutsche Bank, which says the sector's strong start to the year has already pulled forward some optimism.
Read More
AstraZeneca to acquire Modella AI to speed oncology drug research
Published: January 13, 2026 by: Reuters
Sentiment: Positive
AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
Read More
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale
Published: January 13, 2026 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)-- #AstraZeneca--Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale.
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.
Read More
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026
Published: December 24, 2025 by: Proactive Investors
Sentiment: Positive
The festive period is, for some, a time for taking stock of what's happened in the past year - for others, though, its a time to pick stocks for the year ahead. So it is, then, that it's the season for looking ahead.
Read More
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Negative
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
Read More
Here's Why Astrazeneca (AZN) is a Strong Value Stock
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
5 Big Drug Stocks That May Continue to Outperform in 2026
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300